文献速递甲状腺疾病

二肽基肽酶-4稳定整合素α4β1复合物通过激活转化生长因子-β信号通路促进甲状腺癌细胞转移

Dipeptidyl Peptidase-4 Stabilizes Integrin α4β1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway.
PubMed 文献 · Thyroid · 2022-01-01

研究探索DPP4促进甲状腺癌细胞转移的分子机制,发现DPP4在甲状腺乳头状癌中显著上调且与淋巴结转移和BRAFV600E突变正相关;DPP4通过整合素/FAK/AKT/c-Jun/TGF-β1轴诱导上皮-间质转化促进转移,而其酶活性抑制剂西格列汀不影响转移能力,提示DPP4促转移作用不依赖酶活性。

要点

  • DPP4在甲状腺乳头状癌中显著上调,且与淋巴结转移和BRAFV600E突变正相关。
  • DPP4抑制剂西格列汀不影响甲状腺癌细胞转移能力,提示促转移作用不依赖酶活性。
  • DPP4通过整合素/FAK/AKT/c-Jun/TGF-β1信号轴诱导上皮-间质转化促进转移。

核心结论

  • DPP4通过整合素/FAK/AKT/c-Jun/TGF-β1信号轴促进甲状腺癌细胞转移。
  • 这些发现可能对甲状腺癌的替代治疗策略有启示。

研究设计与样本

  • 体外采用Transwell实验评估DPP4对甲状腺癌细胞迁移/侵袭的影响,并建立肺转移小鼠模型以确定DPP4对体内肿瘤转移的作用。
  • 使用DPP4抑制剂西格列汀测试其对甲状腺癌细胞转移的影响,并通过一系列分子和生化实验探索DPP4促进转移的机制。

主要发现

  • 与对照相比,DPP4在甲状腺乳头状癌中显著上调,其表达与淋巴结转移和BRAFV600E突变正相关。
  • 功能研究表明,DPP4敲低显著抑制甲状腺癌细胞的转移潜能,反之亦然。
  • DPP4抑制剂西格列汀不影响甲状腺癌细胞的转移能力,表明DPP4对肿瘤转移的促进作用不依赖其酶活性。
  • 机制上,DPP4与α4和β1整合素亚基相互作用并稳定整合素α4β1复合物的形成。
  • DPP4介导的整合素信号激活通过FAK/AKT通路促进c-Jun核定位,从而诱导转化生长因子-β1(TGFB1,编码蛋白TGF-β1)的转录;TGF-β1随后通过诱导上皮-间质转化促进肿瘤转移。

临床怎么用

  • 作者认为这些发现可能对甲状腺癌的替代治疗策略有启示。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Metastatic disease is a major cause of thyroid cancer-related death. However, the mechanisms responsible for thyroid cancer metastasis are unclear. Dipeptidyl peptidase-4 (DPP4) is a multifunctional cell surface glycoprotein that has been reported to be a negative prognostic factor in thyroid cancer. We explored the molecular mechanism of the role of DPP4 in thyroid cancer cell metastasis. Methods: The effects of DPP4 on thyroid cancer cell migration/invasion in vitro were assessed by transwell assays. A lung metastatic mouse model was also established to determine the effect of DPP4 on tumor metastasis in vivo. DPP4 inhibitor sitagliptin was used to test its effect on thyroid cancer cell metastasis. The mechanism of which DPP4 promotes thyroid cancer cell metastasis was explored by a series of molecular and biochemical experiments. Results: We observed that DPP4 was significantly upregulated in papillary thyroid cancers compared with control subjects, and its expression was positively associated with lymph node metastasis and BRAFV600E mutation. Functional studies showed that DPP4 knockdown significantly inhibited metastatic potential of thyroid cancer cells, and vice versa. However, DPP4 inhibitor sitagliptin did not affect the metastatic ability of thyroid cancer cells, indicating that the promoting effect of DPP4 on tumor metastasis was independent of its enzymatic activity. Mechanistically, DPP4 interacted with the α4 and β1 integrin subunits, and stabilized the formation of integrin α4β1 complex. DPP4-mediated integrin signal activation promoted the nuclear localization of c-Jun through the FAK/AKT pathway, thereby inducing the transcription of transforming growth factor-beta 1 (TGFB1 coding for protein TGF-β1). TGF-β1 then facilitated tumor metastasis by inducing the epithelial-mesenchymal transition. Conclusions: DPP4 promotes thyroid cancer cell metastasis through the integrins/FAK/AKT/c-Jun/TGF-β1 signaling axis. These findings may have implications for an alternative therapeutic strategy for thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. He Q, Cao H, Zhao Y, et al. Dipeptidyl Peptidase-4 Stabilizes Integrin α4β1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway. Thyroid. 2022. PMID: 36166219. doi:10.1089/thy.2022.0317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。